Peripheral Neuropathic Pain - Pipeline Insight, 2024

This “Peripheral Neuropathic Pain - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Peripheral Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral Neuropathic Pain Understanding

Peripheral Neuropathic Pain: Overview

Neuropathic pain is a particularly distressing chronic pain syndrome, affecting between 2% and 8% of people with a major impact on quality of life. Peripheral neuropathic pain, defined as ‘Pain caused by a lesion or disease of the peripheral somatosensory nervous system’, is a common and challenging chronic pain syndrome, with a range of diverse aetiologies. Broadly, these can be divided into neural damage as a result of systemic processes such as disease, toxins, or drugs, often with a classical ‘glove and stocking’ distribution; or secondary to local damage such as trauma, surgery, or locally invasive malignancy.

Symptoms
The symptoms that these pathologies can generate are diverse and include sensations of burning, tingling, lightning bolts of pain, sharp sensations, unpleasant cold sensations, and electric-like sensations. Touching of the skin can cause either allodynia or hyperalgesia. Allodynia is the experience of pain from a stimulus that normally is not painful whereas hyperalgesia is the exaggerated pain response to a painful stimulus. Secondary symptoms and problems can include anxiety, depression, sleep disturbances as well as impairment of quality of life.

Diagnosis
Neuropathic pain syndromes typically have both negative and positive sensory symptoms and signs. Nonsensory neurological symptoms and signs depend on the underlying cause and may independently contribute to pain and disability. Although neuropathic pain has been defined by the International Association for the Study of Pain as pain initiated or caused by a primary lesion or dysfunction in the nervous system,4(p212) several investigators have recently argued that the inclusion of the term dysfunction makes this definition vague and unacceptably broad. A proposed solution is to define neuropathic pain as pain caused by a lesion of the peripheral or central nervous system (or both) manifesting with sensory symptoms and signs. The diagnosis of neuropathic pain is based on a medical history, review of systems, physical and neurological examination, and appropriate laboratory studies including blood and serologic tests, magnetic resonance imaging, and electrophysiologic studies. In some instances, nerve or skin biopsy is necessary to directly visualize nerve fibers.

Management
Neuropathic pain management focuses on treating symptoms, and only in some pathological condition, the etiological causes can be treated relieving pain. The most recent meta-analysis on the drug’s efficacy included a total of 229 studies. The Special Interest Group on Neuropathic Pain (NeuPSIG) proposed gabapentinoids, tricyclic antidepressants (TCAs), and selective serotonin-norepinephrine reuptake inhibitors (SNRI) as the first-line drugs for neuropathic pain. Lidocaine, Capsaicin, and Tramadol have been proposed as the second-line treatment, while strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) were included as third-line treatments for peripheral neuropathic pain.

Peripheral Neuropathic Pain - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Peripheral Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain Emerging Drugs Chapters

This segment of the Peripheral Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Neuropathic Pain Emerging Drugs

HSK16149: Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical Group is developing HSK16149 that is also known as crisugabalin, a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin and is a potent ligand of the voltage-gated calcium channel (VGCC) a2 d subunit. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Peripheral Neuropathic Pain.

AP-325: Algiax PharmaceuticalsAlgiax Pharmaceuticals has discovered AP-325, a unique proprietary small molecule drug compound, to treat neuropathic pain. AP-325 acts as a positive allosteric modulator (PAM) of the GABAA-receptor. GABAA receptor PAMs work via allosteric modulation: they do not bind at the same active site as the natural ligand Gamma-aminobutyric acid (GABAA) but affect the receptor by binding at a different site on the protein. AP-325 is designed to treat a large group of neuropathic pain patients and does not penetrate the brain as such there are no sedative actions that limit their use. Consequently, AP-325 as a non-opioid has a significantly lower potential for addiction or abuse and is truly unique because it is non-sedative, not centrally active and has a long-lasting efficacy. The Drug is currently in Phase II stage of its clinical development for the treatment of Peripheral Post-surgical Neuropathic Pain.

GSK3858279: GlaxoSmithKlineGlaxoSmithKline is developing GSK3858279 for the treatment of Diabetic Peripheral Neuropathic Pain. It is formulated as a solution which is administered through intravenous and subcutaneous routes. It acts by targeting CCL17. The Drug is currently in Phase II stage of its clinical development (NEPTUNE-17) for the treatment of Diabetic Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Neuropathic Pain

There are approx. 8+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II include, Haisco Pharmaceutical Group Co., Ltd.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Neuropathic Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Peripheral Neuropathic Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Neuropathic Pain drugs.

Peripheral Neuropathic Pain Report Insights

• Peripheral Neuropathic Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral Neuropathic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral Neuropathic Pain drugs?
• How many Peripheral Neuropathic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Neuropathic Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Neuropathic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral Neuropathic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Haisco Pharmaceutical Group
• GlaxoSmithKline
• Algiax Pharmaceuticals
• Apurano Pharmaceuticals GmbH
• Eli Lilly and Company
• Shanghai SIMR Biotechnology
• Lexicon Pharmaceuticals

Key Products

• HSK16149
• GSK3858279
• AP-325
• Adezunap
• LY3857210
• SR419
• LX9211

This product will be delivered within 2 business days.